PB-223

N/A

Report date: 2024/12/19 11:40:24

Base Information

Drug NamePB-223
Drug Alias NamePB-223
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsMucin-5AC inhibitors
TargetsMucin-5AC
Therapy Area/IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsHead and Neck Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPrecision Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPrecision Biologics Inc
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsHead and Neck Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A